NCT05241106View on ClinicalTrials.gov

A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 29, 2021

Primary Completion Date

December 30, 2025

Study Completion Date

June 30, 2026

Conditions
Relapsed or Refractory Acute Myeloid Leukemia (AML)
Interventions
DRUG

HYML-122

each treatment cycle is comprised of 28-day consecutive dosing of HYML-122. Upon completion of each cycle, patients may continue to receive oral HYML-122 tablets if they are benefit from the treatment and the toxicity is tolerable.

Trial Locations (1)

215006

RECRUITING

the First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

Tarapeutics Science Inc.

INDUSTRY